Phase 4
N=50
Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler
Nasolabial Folds
Bottom Line
View on ClinicalTrials.gov: NCT01012661 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2010
Primary outcome: Primary: Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain) — 2.8; 6.6 cm
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Radiesse® Injectable Dermal Filler Mixed with Lidocaine (Device); Radiesse® Injectable Dermal Filler without Lidocaine (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merz North America, Inc.
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain) |
2.8; 6.6 | — |
| PRIMARY Patients With Clinically Significant Reduction in Pain |
45; 0 | — |
Summary
To assess pain during nasolabial fold treatment using Radiesse® Injectable Dermal Filler mixed with lidocaine.
Eligibility Criteria
Inclusion Criteria
- Is at least 18 years of age.
- Is a candidate for nasolabial fold treatment using Radiesse.
- Understands and accepts the obligation not to receive any other facial procedures in the lower half of the face for 1 month.
- Understands and accepts the obligation to present for all scheduled follow-up visits and is logistically able to meet all study requirements.
- Has approximately symmetrical nasolabial folds.
Exclusion Criteria
- Has received any type of treatment or procedures including surgery in the nasolabial folds.
- Has received neurotoxins in the lower half of the face in the past 6 months.
- Has received hyaluronic acid, calcium hydroxylapatite (CaHA) or collagen injections in the lower half of the face within past 1 ½ years.
- Has received polylactic acid, polymethyl methacrylate (PMMA), silicone or any other permanent filler in the lower half of the face.
- Has nasolabial folds that are too severe to be corrected in one treatment session.
- Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study.
- Has a known bleeding disorder or is receiving medication that will likely increase the risk of bleeding.
- Is female and of child bearing potential and is pregnant or not using acceptable method of birth control.
- Has had any history of hypersensitivity to Lidocaine or anesthetics of the amide type.
- Has a history of anaphylaxis or multiple severe allergies.
- Has received any investigational product within 30 days prior to study enrollment or is planning to participate in another investigation during the course of this study.
Data sourced from ClinicalTrials.gov (NCT01012661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.